Get the Stockscreener App
30.21
1.69%
-0.52
After Hours:
30.09
-0.12
-0.40%
Vtv Therapeutics Inc stock is traded at $30.21, with a volume of 28,789.
It is down -1.69% in the last 24 hours and down -10.91% over the past month.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
See More
Previous Close:
$30.73
Open:
$30.6
24h Volume:
28,789
Relative Volume:
0.40
Market Cap:
$119.45M
Revenue:
$36.84M
Net Income/Loss:
$-729.00K
P/E Ratio:
-32.71
EPS:
-0.9237
Net Cash Flow:
$-10.02M
1W Performance:
-5.00%
1M Performance:
-10.91%
6M Performance:
-21.12%
1Y Performance:
+32.45%
1-Day Range:
$29.79
$30.91
1-Week Range:
$29.79
$32.38
52-Week Range:
$19.50
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
30.21 | 119.45M | 36.84M | -729.00K | -10.02M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Evercore ISI | Outperform |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Jan-05-26 | Initiated | TD Cowen | Buy |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
Behavioral Patterns of VTVT and Institutional Flows - Stock Traders Daily
vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
vTv Therapeutics at H.C. Wainwright conference: CADI advances By Investing.com - Investing.com Australia
vTv Therapeutics at H.C. Wainwright conference: CADI advances - Investing.com
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
A new hire gets 2,500 options to buy vTv shares at $31.44 each - Stock Titan
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research - marketbeat.com
vTv Therapeutics Q2 2026 Earnings: Net Loss Misses Consensus; No Revenue ReportedEarnings Outlook Update - careplusvn.com
vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - Kalkine
Responsive Playbooks and the VTVT Inflection - news.stocktradersdaily.com
Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy - marketbeat.com
vTv Therapeutics (VTVT) Holds at $33.5 as Shares Consolidate Between Key Support and ResistanceSeasonality Effect - siam.in
vTv Therapeutics (VTVT) Holds Steady at $33.40 as Shares Trade FlatDiamond Pattern - vinanet.vn
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - The Globe and Mail
A type 1 diabetes drug developer plans two investor events in September - Stock Titan
vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving AverageShould You Sell? - marketbeat.com
vTv Therapeutics to Participate in September Investor Conferences - GlobeNewswire
vTv Therapeutics Q2 2026 Earnings: Net Loss Slightly Wider Than Estimates, Shares Edge HigherPerformance Review - dars.gov.et
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High? - qz.com
vTv (VTVT) Outlook: Finishes 0.53% Up at $33.26 in the Current Update; Technical View: Price Remains Between $31.60 Support and $34.92 Resistance on the DayBreakout Stock Alerts - dars.gov.et
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
vTv Therapeutics (VTVT) Slips 2.37% to $30.12 as Support Holds in FocusDouble Top - vinanet.vn
The Technical Signals Behind (VTVT) That Institutions Follow - Stock Traders Daily
vTv Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Lowers Earnings Estimates for vTv Therapeutics - MarketBeat
vTv Therapeutics Inc (VTVT) Reports Q2 Loss of $1.05 Per Share -- What Does a GF Score of 26/100 Indicate? - GuruFocus
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
vTv Therapeutics Inc (VTVT) Stock News Today - TradingKey
vTv Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
vTv Therapeutics (VTVT) Advances Diabetes Treatment Amid High Pr - GuruFocus
VTVT Maintains Buy Rating -- Price Target Lowered to $42.00 by H - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright - MarketBeat
VTv Therapeutics: Q2 Earnings Snapshot - marketscreener.com
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTV THERAPEUTICS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $42 FROM $45 - Bitget
vTv Therapeutics (VTVT) Holds Near $34.45 as Traders Eye $36.17 ResistanceSector ETF Flow - careplusvn.com
VTVT Q2'26 Earnings: revenue estimate is 333.33K USD - TradingView
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Precision Trading with Vtv Therapeutics Inc. (VTVT) Risk Zones - Stock Traders Daily
vTv Therapeutics (VTVT) Edges Down 1% to $32.35, Holding Gains Above Key SupportMotive Wave - dars.gov.et
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageHere's What Happened - marketbeat.com
vTv Therapeutics (VTVT) Slips 1%: Stock Holds Ground Between Key Support and ResistanceETF Inflow Streak - careplusvn.com
vTv Therapeutics Inc. Revenue Breakdown – NASDAQ:VTVT - tradingview.com
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics (VTVT): Millennium entities disclose 6.9% ownership of Class A shares - Stock Titan
vTv Therapeutics Grants Employees Options With 4-Year Vesting - Stock Titan
vTv Therapeutics Inc (VTVT) Cash Flow - TradingKey
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):